$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031943 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$2.350M	$2.398M	$19.74K
YoY Change	682.85%	12047.39%	1406.72%
Cost Of Revenue	$1.440M	$1.408M	$1.234K
YoY Change	1827.82%	113976.99%	722.67%
Gross Profit	$910.2K	$989.9K	$18.50K
YoY Change	306.75%	5249.87%	1495.17%
Gross Profit Margin	38.73%	41.29%	93.75%
Selling, General & Admin	$2.365M	$2.473M	$1.426M
YoY Change	16.83%	73.35%	308.25%
% of Gross Profit	259.78%	249.79%	7708.98%
Research & Development	$274.5K	$402.4K	$335.1K
YoY Change	-16.91%	20.08%	-0.22%
% of Gross Profit	30.16%	40.65%	1811.09%
Depreciation & Amortization	$40.47K	$40.24K	$21.00K
YoY Change	72.22%	91.63%	1919.23%
% of Gross Profit	4.45%	4.07%	113.49%
Operating Expenses	$4.324M	$4.485M	$1.797M
YoY Change	71.71%	149.63%	162.21%
Operating Profit	-$1.974M	-$2.088M	-$1.778M
YoY Change	-13.97%	17.4%	159.95%
Interest Expense	-$19.40K	-$17.06K	$1.360K
YoY Change	-320.83%	-1354.41%	-99.65%
% of Operating Profit
Other Income/Expense, Net	-$24.42K	-$17.06K	$42.76K
YoY Change	144.17%	-139.9%
Pretax Income	-$1.998M	-$2.105M	-$1.736M
YoY Change	-12.69%	21.28%	1871.14%
Income Tax	$2.559K	$5.419K	$4.587K
% Of Pretax Income
Net Earnings	-$2.001M	-$2.110M	-$1.740M
YoY Change	-12.66%	21.27%	1876.35%
Net Earnings / Revenue	-85.13%	-88.01%	-8816.36%
Basic Earnings Per Share	-$0.16	-$0.19	-$0.20
Diluted Earnings Per Share	-$0.16	-$0.19	-$0.20
COMMON SHARES
Basic Shares Outstanding	13.45M shares	11.66M shares	8.519M shares
Diluted Shares Outstanding	12.39M shares	11.39M shares	8.521M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$756.6K	$801.3K	$8.279M
YoY Change	-83.22%	-90.32%	3761.56%
Cash & Equivalents	$800.0K	$800.0K	$8.300M
Short-Term Investments
Other Short-Term Assets	$440.0K	$253.7K	$279.7K
YoY Change	15.8%	-9.28%	181.45%
Inventory	$25.36K	$29.77K	$10.10K
Prepaid Expenses
Receivables	$1.278M	$1.596M	$90.23K
Other Receivables	$49.19K	$0.00	$0.00
Total Short-Term Assets	$2.549M	$2.680M	$8.659M
YoY Change	-57.59%	-69.05%	2546.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$418.2K	$449.3K	$207.4K
YoY Change	-18.35%	116.63%	8032.43%
Goodwill	$1.404M	$1.404M
YoY Change	22.28%
Intangibles	$789.7K	$804.3K
YoY Change	-6.88%
Long-Term Investments
YoY Change
Other Assets	$19.68K	$19.68K	$6.920K
YoY Change	22.52%	184.32%	-98.87%
Total Long-Term Assets	$4.003M	$3.976M	$214.3K
YoY Change	-4.22%	1755.39%	-65.07%
TOTAL ASSETS
Total Short-Term Assets	$2.549M	$2.680M	$8.659M
Total Long-Term Assets	$4.003M	$3.976M	$214.3K
Total Assets	$6.552M	$6.656M	$8.873M
YoY Change	-35.7%	-24.99%	843.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$782.9K	$848.1K	$174.4K
YoY Change	-5.37%	386.29%	-70.19%
Accrued Expenses	$904.3K	$969.1K	$515.7K
YoY Change	40.46%	87.93%	-73.89%
Deferred Revenue
YoY Change
Short-Term Debt	$260.0K	$4.110K	$42.33K
YoY Change		-90.29%	-99.62%
Long-Term Debt Due	$654.9K	$380.3K
YoY Change	81.91%
Total Short-Term Liabilities	$2.491M	$2.326M	$775.2K
YoY Change	27.19%	200.11%	-94.33%
LONG-TERM LIABILITIES
Long-Term Debt	$564.7K	$664.3K	$0.00
YoY Change	-39.28%
Other Long-Term Liabilities	$375.1K	$232.7K
YoY Change	21.01%
Total Long-Term Liabilities	$939.8K	$897.0K	$0.00
YoY Change	-24.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.491M	$2.326M	$775.2K
Total Long-Term Liabilities	$939.8K	$897.0K	$0.00
Total Liabilities	$3.431M	$3.223M	$775.2K
YoY Change	7.37%	315.83%	-94.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$50.70M	-$48.70M	-$39.90M
YoY Change	20.14%	22.06%
Common Stock	$90.06K	$79.41K	$59.89K
YoY Change	39.56%	32.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.121M	$3.433M	$8.098M
YoY Change
Total Liabilities & Shareholders Equity	$6.552M	$6.656M	$8.873M
YoY Change	-35.7%	-24.99%	843.24%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.001M	-$2.110M	-$1.740M
YoY Change	-12.66%	21.27%	1876.35%
Depreciation, Depletion And Amortization	$40.47K	$40.24K	$21.00K
YoY Change	72.22%	91.63%	1919.23%
Cash From Operating Activities	-$1.709M	-$1.532M	-$1.360M
YoY Change	11.71%	12.68%	261.55%
INVESTING ACTIVITIES
Capital Expenditures	$9.410K	$28.28K	$3.870K
YoY Change		630.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$9.410K	-$28.28K	-$3.870K
YoY Change	-99.57%	630.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.674M	-91.15K	-126.1K
YoY Change	-3447.84%	-27.71%	-71.18%
NET CHANGE
Cash From Operating Activities	-1.709M	-1.532M	-1.360M
Cash From Investing Activities	-9.410K	-28.28K	-3.870K
Cash From Financing Activities	1.674M	-91.15K	-126.1K
Net Change In Cash	-44.72K	-1.652M	-1.490M
YoY Change	-98.81%	10.87%	83.12%
FREE CASH FLOW
Cash From Operating Activities	-$1.709M	-$1.532M	-$1.360M
Capital Expenditures	$9.410K	$28.28K	$3.870K
Free Cash Flow	-$1.719M	-$1.561M	-$1.364M
YoY Change	12.33%	14.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20659	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1165844	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1404486	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	833472	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16060	usd
CY2023Q4	us-gaap	Assets Assets	8221552	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	604789	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1149811	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33058	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94708	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2247829	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	835467	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283001	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8221552	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19738	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4804043	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
CY2023Q2	us-gaap	Lease Cost LeaseCost		usd
	us-gaap	Lease Cost LeaseCost		usd
CY2023Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13449165	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	801311	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2821570	usd
CY2024Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1595626	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	811674	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	29768	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	18484	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	253726	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321017	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2680431	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3972745	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	449250	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	458633	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	324942	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	370312	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	973358	usd
CY2024Q2	us-gaap	Goodwill Goodwill	1404486	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	804306	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19675	usd
CY2024Q2	us-gaap	Assets Assets	6656448	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	848102	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	969093	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	26135	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98593	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	380259	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	365463	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	4106	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2326288	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	641566	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	232714	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	22766	usd
CY2024Q2	us-gaap	Liabilities Liabilities	3223334	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3366297	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11487046	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11487046	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9394610	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9394610	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	79407	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	65762	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52030280	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49393972	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48676573	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44604479	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	3433114	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4855255	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6656448	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2397652	usd
CY2024Q2	BIAF	Direct Costs And Expenses DirectCostsAndExpenses	1407710	usd
CY2023Q2	BIAF	Direct Costs And Expenses DirectCostsAndExpenses	1234	usd
	BIAF	Direct Costs And Expenses DirectCostsAndExpenses	2981151	usd
	BIAF	Direct Costs And Expenses DirectCostsAndExpenses	1322	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	402433	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	335125	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	796072	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	704741	usd
CY2024Q2	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	51462	usd
CY2023Q2	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	35260	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	100422	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	54888	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2472775	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1404917	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4658719	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2552792	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	151070	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21552	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300707	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43236	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	4485450	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1798088	usd
	us-gaap	Operating Expenses OperatingExpenses	8837071	usd
	us-gaap	Operating Expenses OperatingExpenses	3356979	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2087798	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1778350	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4033028	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3336320	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	5186	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	44124	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11313	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	82778	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	22249	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1360	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	45799	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3015	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4511	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17062	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	42764	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29975	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	79763	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2104860	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1735586	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4063003	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3256557	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5419	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4587	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9091	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16406	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2110279	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1740173	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4072094	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3272963	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11389308	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11389308	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8520714	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8520714	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10655483	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10655483	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8477656	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8477656	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4855255	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	569907	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74899	usd
	BIAF	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	147	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2500000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	495000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4072094	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	3433114	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	286195	usd
CY2024Q2	BIAF	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	147	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2110279	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	3433114	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	327868	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3272963	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8098348	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9668266	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9668266	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	170255	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1740173	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8098348	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4072094	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3272963	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300707	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43236	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	569907	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	327868	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	783952	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	79743	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11284	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4561	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-63676	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-251292	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	243313	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-170638	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-180718	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-26231	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6923	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	42750	usd
	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	1032	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3878400	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2888990	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69672	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36175	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-69672	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36175	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	495000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2005000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74899	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	147	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	209412	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	26872	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	179105	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1927813	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-209412	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2020259	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3134577	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2821570	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	801311	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8279182	usd
	us-gaap	Interest Paid Net InterestPaidNet	45799	usd
	us-gaap	Interest Paid Net InterestPaidNet	3015	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9091	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16406	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48700000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zdfUOflhX14h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation allowance on the Company’s deferred tax assets, stock-based compensation, valuation of goodwill and intangible assets related to the business combination, allowance for contractual adjustments and discounts related to service revenues, and the useful lives of fixed assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
	us-gaap	Revenues Revenues	3631208	usd
	us-gaap	Profit Loss ProfitLoss	-3765983	usd
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.44
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zpoCcTynJ1W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20240630_z4TLMPXFPvI8" title="Federal insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Advertising Expense AdvertisingExpense	131125	usd
	us-gaap	Advertising Expense AdvertisingExpense	27741	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	119205	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	21692	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9176479	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5456344	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4804043	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20659	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2254486	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-45694	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2298792	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29167	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14538	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2397652	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19738	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4804043	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20659	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2087798	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1778350	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4033028	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3336320	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17062	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	42764	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29975	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	79763	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2104860	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1735586	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4063003	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3256557	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5419	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4587	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9091	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16406	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2110279	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1740173	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4072094	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3272963	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	796072	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	704741	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	402433	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	335125	usd
CY2024Q2	BIAF	Patient Service Fees PatientServiceFees	1279413	usd
CY2023Q4	BIAF	Patient Service Fees PatientServiceFees	657717	usd
CY2024Q2	BIAF	Histology Fees HistologyFees	193810	usd
CY2023Q4	BIAF	Histology Fees HistologyFees	121301	usd
CY2024Q2	BIAF	Medical Director Fees MedicalDirectorFees	3040	usd
CY2023Q4	BIAF	Medical Director Fees MedicalDirectorFees	3103	usd
CY2024Q2	us-gaap	Other Receivables OtherReceivables	119363	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	29553	usd
CY2024Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1595626	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	811674	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	77427	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	171855	usd
CY2024Q2	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	50304	usd
CY2023Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	24476	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	125995	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	124686	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	253726	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321017	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	902224	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	831756	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	452974	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	373123	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	449250	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	458633	usd
	us-gaap	Depreciation Depreciation	79054	usd
	us-gaap	Depreciation Depreciation	41000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	40243	usd
CY2023Q2	us-gaap	Depreciation Depreciation	21000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	749709	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	857037	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	162318	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	257926	usd
CY2024Q2	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	55315	usd
CY2023Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	15350	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1751	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19498	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	969093	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1149811	usd
CY2024Q2	us-gaap	Deferred Revenue DeferredRevenue	26135	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	33058	usd
CY2024Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y29D
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	96243	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	192486	usd
CY2024Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	22235	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	45785	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	29916	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	59831	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	148394	usd
	us-gaap	Lease Cost LeaseCost	298102	usd
CY2024Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	88665	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	179105	usd
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	516	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1032	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	324942	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	370312	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98593	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94708	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	232714	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283001	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1294168	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1294168	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	320810	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	128324	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	973358	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1165844	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	380259	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	365463	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	641566	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	835467	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	1021825	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1200930	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M29D
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M25D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0807	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0807	pure
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0802	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0801	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	60863	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	224252	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	121726	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	448505	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	121726	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	270395	usd
CY2024Q2	BIAF	Lessee Operating Lease Liability Payments Due Year Three And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter	71007	usd
CY2024Q2	BIAF	Finance Lease Liability Payments Due Year Three And Thereafter FinanceLeaseLiabilityPaymentsDueYearThreeAndThereafter	202970	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	375322	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1146122	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	44015	usd
CY2024Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	124297	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	331307	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	1021825	usd
	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	26872	usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	4106	usd
	us-gaap	Payments For Rent PaymentsForRent	60000	usd
	us-gaap	Payments For Rent PaymentsForRent	53000	usd
CY2024Q2	us-gaap	Payments For Rent PaymentsForRent	31000	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	26000	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	287294	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	170254	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	569907	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	327868	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	8838717	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	4649952	shares
CY2024Q2	BIAF	Number Of Warrants Issued NumberOfWarrantsIssued	9875202	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.53
CY2024Q2	BIAF	Number Of Warrants Exercised NumberOfWarrantsExercised	-1036534	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8838669	shares
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-031943-index-headers.html	Edgar Link	pending
0001493152-24-031943-index.html	Edgar Link	pending
0001493152-24-031943.txt	Edgar Link	pending
0001493152-24-031943-xbrl.zip	Edgar Link	pending
biaf-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
biaf-20240630_def.xml	Edgar Link	unprocessable
biaf-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
biaf-20240630_cal.xml	Edgar Link	unprocessable
biaf-20240630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2024 Q3 Form 10-Q Financial Statement

#000149315224031943 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2024 Q3 Form 10-Q Financial Statement

#000149315224031943 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf